Nasdaq4d
Aclarion Secures Notice of Allowance for 24th US Patent Expanding MRS Use in Identifying Propionic Acid as a Biomarker for Infection and Pain
Aclarion is recognized for leveraging MRS technology to improve the diagnosis of chronic low back pain through its Nociscan platform, which assists physicians in distinguishing between painful and ...
Investing4d
Aclarion secures patent for infection, pain biomarker detection
The company's Nociscan platform is the first software as a service (SaaS) product to noninvasively help physicians differentiate between painful and non-painful discs in the lumbar spine. By analyzing ...
Investing4d
Aclarion secures patent for infection, pain biomarker detection
The company's Nociscan platform is the first software as a service (SaaS) product to noninvasively help physicians differentiate between painful and non-painful discs in the lumbar spine.
Aclarion Wins Patent, Shares Eke Up
Aclarion, Inc. (NASDAQ: ACON) shares cleared breakeven Tuesday, as the health-care technology company announced it has received a Notice of Allowance from the United States Patent and Trademark Office ...
Yahoo Finance2d
Aclarion, Inc. (ACON)
Recent Notice of Allowance is for Aclarion’s 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an ...
Aclarion stock hits 52-week low at $4.41 amid steep annual decline
In a challenging year for Aclarion, the medical technology company's stock has plummeted to a 52-week low, trading at $4.41. According to InvestingPro data, the company maintains a healthy liquidity ...